Has India’s Drug Pricing Authority Been Rendered Toothless?
Executive Summary
India has put in place a new panel to act as a 'recommending body' to the National Pharmaceutical Pricing Authority, raising questions about the pricing body’s autonomy and whether its role has been 'usurped'. The pharma industry claims a balanced pricing regime may emerge under the new system but doesn’t rule out inter-department conflicts in the government.
You may also be interested in...
India’s Pricing Authority Has New Chief, Again
India’s National Pharmaceutical Pricing Authority has a new chief, and pharma hopes that pricing policy outlook on the domestic market remains stable against the backdrop of a challenging operating environment globally.
India's Device Price Cap Storm Rages On: New Stent Cap And Spotlight On Catheter Trade Margins
India’s medical device pricing storm looks unlikely to abate any time soon, with another round of price caps on stents being enforced. The spotlight is also shining on the sharp variances in trade margins for catheters in the country.
Indian Drug Price Regulator Opposes Plans To Clip Its Wings
An Aug. 30 stakeholder meeting on India’s contentious draft pharmaceutical policy was an unusual mix of radical suggestions, simmering tensions and a changed agenda. With voices of opposition growing, including from within the government, it’s unlikely to be smooth sailing for the draft, at least in its current form.